Dynavax to Present at the JMP Securities Healthcare Conference

(firmenpresse) - BERKELEY, CA -- (Marketwired) -- 07/02/13 -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that it will present at the JMP Securities Healthcare Conference in New York on Wednesday, July 10 at 9:00 a.m. EDT (6:00 a.m. PDT).

Michael Ostrach, Chief Business Officer of Dynavax, will provide a corporate overview presentation. To access the slide presentation, live webcast, and subsequent archived recording, please visit Dynavax's website at .



Dynavax, a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious and inflammatory diseases. Dynavax's lead product candidate is HEPLISAV™, a Phase 3 investigational adult hepatitis B vaccine. For more information visit .



Michael Ostrach
Vice President and Chief Business Officer
510-665-7257

Weitere Infos zu dieser Pressemeldung:

Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: Marketwired
Datum: 02.07.2013 - 13:00 Uhr
Sprache: Deutsch
News-ID 275067
Anzahl Zeichen: 0

contact information:
Town:

BERKELEY, CA

Kategorie:

Biotech

Diese Pressemitteilung wurde bisher 204 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Dynavax to Present at the JMP Securities Healthcare Conference"
steht unter der journalistisch-redaktionellen Verantwortung von

Dynavax Technologies (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

Dynavax Presents Clinical Data From Lead Cancer Immunotherapy Candidate, SD-101, ...

BERKELEY, CA -- (Marketwired) -- 12/05/15 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced clinical data from an ongoing Phase 1/2 clinical trial evaluating intratumoral administration of SD-101 in the treatment of low-grade lympho ...

Dynavax Announces Presentation of Clinical Data at ASH Annual Meeting ...

BERKELEY, CA -- (Marketwired) -- 11/30/15 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that it will present clinical data at the 57th American Society of Hematology (ASH) Annual Meeting this weekend in Orlando, Florida. The det ...

Dynavax Reports Third Quarter 2015 Financial Results ...

BERKELEY, CA -- (Marketwired) -- 11/05/15 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for the third quarter ended September 30, 2015.The Company had $220.7 million in cash, cash equivalents and marketable secu ...

Alle Meldungen von Dynavax Technologies